Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P511

Utilisation and efficacy of oral iron therapy in patients with iron deficiency anaemia in a nationwide cohort of ulcerative colitis patients

Authors:

D. Patel*1, N. Khan2

1Mercy Catholic Medical Centre, Internal Medicine, Philadelphia, Pennsylvania, United States, 2University of Pennsylvania, Internal Medicine, Philadelphia, Pennsylvania, United States

P512

The prevalence and risk factors of gallstone disease in patients with ulcerative colitis

Authors:

B. I. Jang*1, K. O. Kim1, C. H. Yang2, Y. H. Jung1

1Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea, 2Dongguk University College of Medicine, Division of gastroenterology and Hepatology, department of Internal Medicine, Kyungju, Korea, Republic of

P513

Comparison of infliximab the originator and biosimilars in treatment of Crohn’s disease: a Polish cohort study

Authors:

E. Zagorowicz*1, J. Kierkuś2, M. Kłopocka3, K. Stec-Michalska4, R. Talar-Wojnarowska4, L. Łykowska-Szuber5, I. Detka-Kowalska6, A. Meder3, A. Pietrzak1, D. Maj7, M. Kowalski8, J. Wójcik9, W. Ruczak10, T. Arłukowicz11, M. Włodarczyk4, A. Śliwczyński4, 12, M. Gonciarz13

1Institute of Oncology, Gastroenterology, Warsaw, Poland, 2Children’s Memorial Health Institute, Warsaw, Poland, 3Collegium Medicum, Bydgoszcz, Poland, 4Medical University, Łódź, Poland, 5University of Medical Sciences, Poznań, Poland, 6District Hospital, Końskie, Poland, 7Military Institute of Medicine, Warsaw, Poland, 8Barska Hospital, Włocławek, Poland, 9District Hospital, Lublin, Poland, 10District Hospital, Przemyśl, Poland, 11District Hospital, Olsztyn, Poland, 12National Health Fund, Warsaw, Poland, 13Corpora-Med, Gliwice, Poland

P514

Proximal extension of distal lesions in patients with ulcerative colitis

Authors:

T. Sato*1, M. Kawai2, K. Kamikozuru1, Y. Kita1, Y. Yokoyama1, T. Takagawa3, T. Miyazaki1, M. Iimuro1, N. Hida1, K. Hori1, S. Nakamura1

1Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Nishinomiya, Japan, 2Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Nishinomiya, Japan, 3Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Nisinomiya, Japan

P515

Biosimilar candidate ABP 501: immunogenicity results from 2 phase 3 studies

Authors:

P. Kaur*1, E. Krishnan1, N. Zhang1, A. Kaliyaperumal2

1Amgen, Inc., Biosimilars Division, Thousand Oaks, California, United States, 2Amgen, Inc., Clinical Immunology & BSM, Thousand Oaks, California, United States

P516

A prospective 24-week mucosal healing and deep-remission assessment of small bowel and colonic Crohn’s disease as detected by colon capsule endoscopy

Authors:

S. Oliva*1, S. Cohen2, F. Civitelli1, M. Aloi1, F. Viola1, E. Casciani3, F. Maccioni4, C. Hassan5, P. Papoff6, S. Cucchiara1

1Sapienza - University of Rome, Department of Paediatrics, Paediatric Gastroenterology and Liver Unit, Rome, Italy, 2Children’s Centre for Digestive Health Care, Atlanta, United States, 3Sapienza - University of Rome, Department of Emergency Radiology, Rome, Italy, 4Sapienza - University of Rome, Department of Radiological Sciences, Oncology, and Pathology, Rome, Italy, 5Nuovo Regina Margherita Hospital, Gastroenterology Department, Rome, Italy, 6Sapienza - University of Rome, Department of Paediatrics PICU, Rome, Italy

P517

Cognitive-behavioural therapy has no effect on disease activity but it improves quality of life in sub-groups of patients with inflammatory bowel disease short-term: a randomised controlled trial with a 24-month follow-up

Authors:

A. Mikocka-Walus1, J. Andrews*2, P. Bampton3, D. Hetzel2, P. Hughes4, A. Esterman5

1University of York, Health Sciences, York, United Kingdom, 2Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Q7 North Wing, Adelaide, Australia, 3Flinders Medical Centre, Department of Gastroenterology, Adelaide, Australia, 4University of Adelaide, Nerve-Gut Research Laboratory, Discipline of Medicine, Adelaide, Australia, 5University of South Australia, School of Nursing and Midwifery, Adelaide, Australia

P518

Aberrant adipose tissue partitioning with abdominal obesity, defined by MRI, is a hallmark of paediatric Crohn’s disease

Authors:

D. Thangarajah*1, K. E. Chapell1, S. Mandalia1, G. Frost2, J. M. Fell3

1Imperial College, Section of Academic Neonatal Medicine, London, United Kingdom, 2Imperial College, Nutrition and Dietetic Research Group, Faculty of Medicine, London, United Kingdom, 3Chelsea and Westminster Hospital NHS Foundation Trust, Department of Paediatric Gastroenterology, London, United Kingdom

P519

Efficacy and safety of biosimilar of infliximab (Inflectra) in adult patients with Crohn’s disease during 1 year of treatment, followed 6 months of observation: a one-centre retrospective study

Authors:

M. Kaniewska*1, G. Rydzewska1, 2

1Central Clinical Hospital of the Ministry of Interior, Department of Gastroenterology, Warsaw, Poland, 2Faculty of Health Science Jan Kochanowski University, Kielce, Poland

P520

Therapeutic drug monitoring in 45 children with inflammatory bowel disease on maintenance infliximab treatment

Authors:

H. Rolandsdotter1, 2, P. Marits2, 3, U. Sundin3, A.-C. Wikström2, 3, U. Fagerberg2, 4, Y. Finkel1, 2, M. Eberhardson*2, 5

1Sachs’ Children and Youth Hospital, Department of Gastroenterology, Stockholm, Sweden, 2Karolinska Institute, Stockholm, Sweden, 3Karolinska University Hospital, Department of Clinical immunology and Transfusion Medicine, Stockholm, Sweden, 4Vastmanland Hospital Vasteras, Centre for Clinical Research, Vasteras, Sweden, 5Karolinska University Hospital, Centre for Digestive Diseases, Stockholm, Sweden

P521

Anti-TNF serum level and clinical, radiological or endoscopical response in luminal and perianal Crohn’s disease: results of the OPTIMIZA study

Authors:

A. Echarri*1, R. Ferreiro2, R. Fraga1, J. Cid3, M. Barreiro de Acosta2, S. Pereira4, J. Pineda4, D. Carpio5, S. Soto6, E. Castro7, J. Gallego8, B. Gonzalez9, A. Carmona10

1Complejo Hospitalario Ferrol, Gastroenterology, Ferrol, Spain, 2Complejo Hospitalario Universitario Santiago, Gastroenterology, Santiago, Spain, 3Complejo Hospitalario Coruña, Immunology, Coruña, Spain, 4Complejo Hospitalario Vigo, Gastroenterology, Vigo, Spain, 5Complejo Hospitalario Pontevedra, Gastroenterology, Pontevedra, Spain, 6Complejo Hospitalario Orense, Gastroenterology, Orense, Spain, 7Complejo Hospitalario Lugo, Gastroenterology, Lugo, Spain, 8Complejo Hospitalario Ferrol, Radiology, Ferrol, Spain, 9Complejo Hospitalario Coruña, Gastroenterology, Coruña, Spain, 10Povisa, Gastroenterology, Vigo, Spain

P522

A multicentre open-label study assessing pharmacokinetics, efficacy, and safety of subcutaneous golimumab in paediatric patients with moderately to severely active ulcerative colitis

Authors:

D. Turner*1, G. Veereman2, J. Hyams3, A. Griffiths4, D. Chan5, O. J. Adedokun5, L. Damaraju5, R. Strauss5

1Shaare Zedek Medical Centre, The Hebrew University of Jerusalem, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, 2Free University Brussels, Brussels, Belgium, 3Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 4The Hospital for Sick Children, Toronto, Canada, 5Janssen R & D, LLC, Spring House, Pennsylvania, United States

P523

Identifying ‘at-risk’ inflammatory bowel disease patients who may be targeted with a new adjuvant herpes zoster subunit vaccine

Authors:

W. Bye*1, M. Sparrow2, S. J. Connor3, J. M. Andrews4, K. Ellard5, W. Ng3, G. Hume6, S. Antoniades1, A. J. Walsh1

1St Vincent’s Hospital, Department of Gastroenterology, Sydney, Australia, 2The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia, 3South Western Sydney Local Health District, Liverpool Hospital, Department of Gastroenterology, Sydney, Australia, 4Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia, 5Private practice, Sydney, Australia, 6Mater Hospital, Brisbane, Australia

P524

Pharmacokinetics of adalimumab in paediatric subjects with moderate versus severe Crohn’s disease in Imagine-1

Authors:

R. Singh*1, B. Kluender2, A. Robinson1, A. Lazar2, R. Thakkar1, N. Mostafa1

1AbbVie, North Chicago, United States, 2AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

P525

The combined cell therapy and anticytokine therapy of adalimumab promotes deep remission (immunobiological and histology) of Crohn’s disease

Authors:

O. Knyazev1, A. Kagramanova*1, S. Khomeriki2, A. Konoplyannikov3, K. Noskova4, N. Fadeeva5, A. Parfenov1

1Moscow Clinical Research Centre, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 2Moscow Clinical Research Centre, Department of Pathology, Moscow, Russian Federation, 3Medical Radiological Scientific Centre, Department of Stem Cells Therapy, Obninsk, Russian Federation, 4Moscow Clinical Research Centre, Department of Laboratory, Moscow, Russian Federation, 5Moscow Clinical Research Centre, Department of Inflammatory Bowel Disease, Moscow, Russian Federation

P526

Sampling not at trough: adalimumab serum drug and antibody levels remain relatively stable in between injections

Authors:

B. Ungar*1, M. Yavzori1, O. Picard1, E. Fudim1, U. Kopylov1, Y. Chowers2, R. Eliakim1, S. Ben-Horin1

1Sheba Medical Centre & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, 2Rambam Health Care Campus, Bruce & Ruth Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel

P527

Frequency and predictors of azathioprine induced pancreatitis amongst inflammatory bowel disease patients: results of a tertiary referral centre

Authors:

N. Demir*1, T. Eskazan2, Y. Erzin2, I. Hatemi2, S. Bozcan2, K. Atay2, A.F. Celik2

1Istanbul university Cerrahpasa medical school, Gastroenterology, Istanbul, Turkey, 2IstanbuI university Cerrahpasa medical school, Gastroenterology, Istanbul, Turkey

P528

Comparison of short-term and long-term outcomes between Anti-TNF-antibodies and tacrolimus for refractory ulcerative colitis patients

Authors:

T. Ishida*1, T. Ueo1, R. Narita1, M. Motomura1, Y. Yanai1, K. Wada1, H. Honda1, S. Inoue1, K. Murakami2

1Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, 2Oita University, Department of Gastroenterology, Oita, Japan

P529

Efficacy and safety of infliximab versus adalimumab in the treatment of Crohn’s disease: The McGill Experience

Authors:

T. Al-Taweel*1, 2, M. Strohl2, U. Kopylov2, L. Paradis-Suprenant2, M. Almaimany2, M. Martel2, A. Bitton2, W. Afif2, T. Bessissow2

1Mubarak Al-Kabeer Hospital, Haya Al-Habeeb Gastroenterology Centre, Hawally, Kuwait, 2McGill University Health Centre, Division of Gastroenterology, Montreal, Canada

P530

Efficacy of biosimilar infliximab induction therapy in paediatric patients with Crohn’s disease: 1.5 years of experience

Authors:

J. Sieczkowska*1, A. Plocek2, A. Banaszkiewicz3, D. Jarzebicka1, A. Gawronska3, E. Toporowska-Kowalska2, J. Kierkus1

1The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 2Medical University of Łódź, Department of Paediatric Allergology, Gastroenterology and Nutrition, Łódź, Poland, 3Medical University of Warsaw, Department of Paediatric Gastroenterology and Nutrition, Warsaw, Poland